Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients

Sandhya Sandhya, Tara L Hogenson & Martin E Fernandez-Zapico*

Standard-of-care regimens for pancreatic ductal adenocarcinoma (PDAC) include a combination of chemotherapies, which are associated with toxicity and eventually tumor resistance. The lack of relevant tool to identify and evaluate new therapies in PDAC necessitates the search for a model, especially for cases with treatment resistance to standard of care. In the current issue, Peschke et al (2022) describe a longitudinal platform to identify drug-induced vulnerabilities following standard-of-care chemotherapy treatment using patient-derived organoids (PDOs) providing an opportunity to predict therapeutic response and define new treatment vulnerability induced by standard of care. Previously, tumor resistance to chemotherapy has typically been described as selection for resistant tumor cell populations. However, Peschke et al (2022) demonstrated that PDAC cells seemed to acquire resistance not only through genetic changes, but also through modifications in cellular plasticity leading to gene expression and metabolism changes. Thus, the study supports this type of platform for the identification of new therapeutic targets following standard-of-care treatments in PDAC.

EMBO Mol Med (2022) 14: e15707
See also: K Peschke et al (April 2022)

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer of the pancreas with a 5-year survival rate of ~10%. Early metastatic progression, highly resistant to all current standard-of-care therapies including radio-, and chemotherapy, makes it a devastating disease (Orth et al, 2019). Surgical resection along with chemotherapy has curative potential but is only applicable to ~20% of cases since the majority of patients are diagnosed with advanced disease and are not candidate for surgical resection. Commonly used regimens for PDAC treatment include gemcitabine (Gem) + nab-paclitaxel or FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin). Though between-trial comparisons are not statistically valid, the perceived efficacy of FOLFIRINOX makes it the preferred first-line treatment option in fit patients. Additionally, Gem-based regimens are reserved for less fit or elderly patients due to superior tolerability. These chemotherapy regimens are associated with inevitable toxicity and resistance and only increase the median survival for approximately a year. Thus, if individualized chemotherapy sensitivity in relevant models can be predicted, anticipated efficacy could be enhanced while minimizing toxicity.

Cell lines, mice xenograft, and genetically engineered mice are the widely used models to evaluate therapeutic responses, but they do not closely represent the genetic and epi-genetic landscape of each PDAC patient. Tumor tissues derived from patient are considered most representative but are associated with limitations such as availability and low amount. Apart from these, tumors are good for molecular profiling but are not suitable for pharmacological testing, which is the current requirement for PDAC treatment where patients show very high variability to drug response. To circumvent the limitations of the above models, patient-derived organoids (PDOs) provide advantages by being evolved as a reliable model to predict the drug response in cells having characteristics of individual patient tumors. Also, these 3-dimensional (3D) cultures have heterogeneous structures mimicking the in vivo tumor architecture. Studies show PDO responses to drug correlate well with the genomic profile of the patient tumor with a high sensitivity and specificity (Grossman et al., 2022).

In the current issue, Peschke et al (2022) describe the development of a longitudinal precision oncology platform to gain insights into chemotherapy-induced vulnerabilities, to improve treatment response in the clinical setting. Using generated PDOs derived from biopsy and resection samples of a patient before and after FOLFIRINOX treatment, the authors found PDOs show re-differentiation post-FOLFIRINOX treatment. They also found there was a treatment-induced metabolic switch from aerobic glycolysis to oxidative phosphorylation and increased lipid metabolism in the resistant PDO. In addition, RNA-seq analysis of these pre- and post-chemotherapy PDOs found similar classical subtype for both the models. In fact, characteristic pathways of basal-like subtype were more enriched in PDO before chemotherapy treatment. The molecular switching of pathways from basal-like subtype to classical following FOLFIRINOX therapy may provide a proliferate advantage and possibly in the development of resistant phenotype (Chan-Seng-Yue et al., 2020; Grünwald et al., 2021). Importantly, this study showed the adaptive response of the
The authors demonstrate a vulnerability of cancer cells following chemotherapy treatment that is independent of genetic mechanisms. This demonstrates a need for additional testing using PDOs to identify new treatment regimens for sensitivity that evaluate more than the genetic landscape of the tumor. Additional studies examining these new pathways altered following chemotherapy treatment could benefit PDAC treatment options. The PDO model used in the study makes it a highly reliable and specific model for studying these mechanisms. This demonstrates another potential use of PDOs for identifying new cancer therapies for PDAC patients.

References

Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O’Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J et al (2020) Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet 52: 231 – 240

Grossman JE, Muthuswamy L, Huang L, Akshinthala D, Perea S, Gonzalez RS, Tsai LL, Cohen J, Bockorny B, Bullock AJ et al (2022) Organoid sensitivity correlates with therapeutic response in patients with pancreatic cancer. Clin Cancer Res 28: 708 – 718

Grünwald BT, Devisme A, Andrieux G, Vyas F, Aliar K, McCloskey CW, Macklin A, Jang GH, Denroche R, Romero JM et al (2021) Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184: 5577 – 5592

Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K (2019) Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 14: 141

Peschke K, Jakubowsky H, Schäfer A, Maurer C, Lange S, Orben F, Bernad R, Harder FN, Eiber M, Ollinger R et al (2022) Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med 14: e14876

License: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.